1-20 of 36
Charles M. Perou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors

Hyunsoo Kim, Austin A. Whitman, Kamila Wisniewska, Rasha T. Kakati, Susana García-Recio, Benjamin C. Calhoun, Hector L. Franco, Charles M. Perou, Philip M. Spanheimer
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1248
Published: 25 September 2023
View article titled, Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
Open the PDF for Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors in another window
Includes: Supplementary data
Journal Articles

Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

Holly Tovey, Orsolya Sipos, Joel S. Parker, Katherine A. Hoadley, Jelmar Quist, Sarah Kernaghan, Lucy Kilburn, Roberto Salgado, Sherene Loi, Richard D. Kennedy, Ioannis Roxanis, Patrycja Gazinska, Sarah E. Pinder, Judith Bliss, Charles M. Perou, Syed Haider, Anita Grigoriadis, Andrew Tutt, Maggie Chon U. Cheang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3691–3705.
https://doi.org/10.1158/1078-0432.CCR-23-0370
Published: 15 September 2023
View article titled, Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
Open the PDF for Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727) in another window
Includes: Supplementary data
Journal Articles

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer

Youli Xia, Xiaping He, Lorna Renshaw, Carlos Martinez-Perez, Charlene Kay, Mark Gray, James Meehan, Joel S. Parker, Charles M. Perou, Lisa A. Carey, J. Michael Dixon, Arran Turnbull
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3618–3629.
https://doi.org/10.1158/1078-0432.CCR-21-3189
Published: 15 August 2022
View article titled, Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
Open the PDF for Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

Tomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Núria Chic, Maria Vidal, Barbara Adamo, Montserrat Muñoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Paré, Patricia Galvan, Lisa A. Carey, Charles M. Perou, Aleix Prat
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3116–3125.
https://doi.org/10.1158/1078-0432.CCR-20-4102
Published: 01 June 2021
View article titled, Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy
Open the PDF for Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy in another window
Includes: Supplementary data
Journal Articles

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4670–4681.
https://doi.org/10.1158/1078-0432.CCR-20-0389
Published: 01 September 2020
View article titled, Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Open the PDF for Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy

Adrienne G. Waks, Daniel G. Stover, Jennifer L. Guerriero, Deborah Dillon, William T. Barry, Evisa Gjini, Christina Hartl, Wesley Lo, Jennifer Savoie, Jane Brock, Robert Wesolowski, Zaibo Li, Adrienne Damicis, Anne V. Philips, Yun Wu, Fei Yang, Amy Sullivan, Patrick Danaher, Heather Ann Brauer, Wafa Osmani, Mikel Lipschitz, Katherine A. Hoadley, Michael Goldberg, Charles M. Perou, Scott Rodig, Eric P. Winer, Ian E. Krop, Elizabeth A. Mittendorf, Sara M. Tolaney
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4644–4655.
https://doi.org/10.1158/1078-0432.CCR-19-0173
Published: 01 August 2019
View article titled, The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Open the PDF for The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Priyanka Sharma, Sara López-Tarruella, José Angel García-Saenz, Qamar J. Khan, Henry L. Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Agustí Barnadas, Antoni C. Picornell, María del Monte-Millán, Milagros González-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González del Val, Javier Cortés, Hugo Fuentes-Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M. Perou, Carolyn Lehn, Yen Y. Wang, Jennifer R. Klemp, Joshua V. Mammen, Jamie L. Wagner, Amanda L. Amin, Anne P. O’Dea, Jaimie Heldstab, Roy A. Jensen, Bruce F. Kimler, Andrew K. Godwin, Miguel Martín
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5820–5829.
https://doi.org/10.1158/1078-0432.CCR-18-0585
Published: 03 December 2018
View article titled, Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Open the PDF for Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel in another window
Includes: Supplementary data
Journal Articles

Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

Maki Tanioka, Cheng Fan, Joel S. Parker, Katherine A. Hoadley, Zhiyuan Hu, Yan Li, Terry M. Hyslop, Brandelyn N. Pitcher, Matthew G. Soloway, Patricia A. Spears, Lynn N. Henry, Sara Tolaney, Chau T. Dang, Ian E. Krop, Lyndsay N. Harris, Donald A. Berry, Elaine R. Mardis, Eric P. Winer, Clifford A. Hudis, Lisa A. Carey, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (21): 5292–5304.
https://doi.org/10.1158/1078-0432.CCR-17-3431
Published: 01 November 2018
View article titled, Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Open the PDF for Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Isabel Echavarria, Sara López-Tarruella, Antoni Picornell, Jose Ángel García-Saenz, Yolanda Jerez, Katherine Hoadley, Henry L. Gómez, Fernando Moreno, María Del Monte-Millan, Iván Márquez-Rodas, Enrique Alvarez, Rocío Ramos-Medina, Javier Gayarre, Tatiana Massarrah, Inmaculada Ocaña, María Cebollero, Hugo Fuentes, Agusti Barnadas, Ana Isabel Ballesteros, Uriel Bohn, Charles M. Perou, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1845–1852.
https://doi.org/10.1158/1078-0432.CCR-17-1912
Published: 12 April 2018
View article titled, Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
Open the PDF for Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification in another window
Includes: Supplementary data
Journal Articles

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts

Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Claudette Falato, Joseph W. Carlson, Paul K. Wright, Theodoros Foukakis, Charles M. Perou, Kamila Czene, Jonas Bergh, Nicholas P. Tobin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7512–7520.
https://doi.org/10.1158/1078-0432.CCR-17-1535
Published: 14 December 2017
View article titled, Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Open the PDF for Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts in another window
Includes: Supplementary data
Journal Articles

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients

Nicholas P. Tobin, Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Theodoros Foukakis, Lena Carlsson, Zakaria Einbeigi, Barbro K. Linderholm, Niklas Loman, Martin Malmberg, Mårten Fernö, Kamila Czene, Charles M. Perou, Jonas Bergh, Thomas Hatschek
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (23): 7225–7231.
https://doi.org/10.1158/1078-0432.CCR-17-2301
Published: 30 November 2017
View article titled, PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Open the PDF for PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Aleix Prat, Ana Lluch, Arran K. Turnbull, Anita K. Dunbier, Lourdes Calvo, Joan Albanell, Juan de la Haba-Rodríguez, Angels Arcusa, José Ignacio Chacón, Pedro Sánchez-Rovira, Arrate Plazaola, Montserrat Muñoz, Laia Paré, Joel S. Parker, Nuria Ribelles, Begoña Jimenez, Abdul Aziz Bin Aiderus, Rosalía Caballero, Barbara Adamo, Mitch Dowsett, Eva Carrasco, Miguel Martín, J. Michael Dixon, Charles M. Perou, Emilio Alba
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (12): 3035–3044.
https://doi.org/10.1158/1078-0432.CCR-16-2092
Published: 14 June 2017
View article titled, A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse
Open the PDF for A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse in another window
Includes: Supplementary data
Journal Articles

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

Priyanka Sharma, Sara López-Tarruella, Jose Angel García-Saenz, Claire Ward, Carol S. Connor, Henry L. Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Augusti Barnadas, Antoni C. Picornell, Maria del Monte-Millán, Milagros Gonzalez-Rivera, Tatiana Massarrah, Beatriz Pelaez-Lorenzo, María Isabel Palomero, Ricardo González del Val, Javier Cortes, Hugo Fuentes Rivera, Denisse Bretel Morales, Iván Márquez-Rodas, Charles M. Perou, Jamie L. Wagner, Joshua M.V. Mammen, Marilee K. McGinness, Jennifer R. Klemp, Amanda L. Amin, Carol J. Fabian, Jaimie Heldstab, Andrew K. Godwin, Roy A. Jensen, Bruce F. Kimler, Qamar J. Khan, Miguel Martin
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (3): 649–657.
https://doi.org/10.1158/1078-0432.CCR-16-0162
Published: 31 January 2017
View article titled, Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Open the PDF for Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts in another window
Includes: Supplementary data
Journal Articles

High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype

Jennifer B. Dennison, Maria Shahmoradgoli, Wenbin Liu, Zhenlin Ju, Funda Meric-Bernstam, Charles M. Perou, Aysegul A. Sahin, Alana Welm, Steffi Oesterreich, Matthew J. Sikora, Robert E. Brown, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (20): 5068–5078.
https://doi.org/10.1158/1078-0432.CCR-16-0171
Published: 13 October 2016
View article titled, High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype
Open the PDF for High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping

Torsten O. Nielsen, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (8): 1779–1781.
https://doi.org/10.1158/1078-0432.CCR-14-2552
Published: 14 April 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping in another window
Journal Articles

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models

Gina Song, David B. Darr, Charlene M. Santos, Mark Ross, Alain Valdivia, Jamie L. Jordan, Bentley R. Midkiff, Stephanie Cohen, Nana Nikolaishvili-Feinberg, C. Ryan Miller, Teresa K. Tarrant, Arlin B. Rogers, Andrew C. Dudley, Charles M. Perou, William C. Zamboni
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 6083–6095.
https://doi.org/10.1158/1078-0432.CCR-14-0493
Published: 30 November 2014
View article titled, Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models
Open the PDF for Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models in another window
Includes: Supplementary data
Journal Articles

Predictions of breast cancer local and distant metastasis

Zhiyuan Hu, He Xiaping, Matthew Ewend, Charles M. Perou
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19_Supplement): A79.
Published: 15 August 2014
View article titled, Predictions of breast cancer local and distant metastasis
Journal Articles

Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer

Michael D. Iglesia, Benjamin G. Vincent, Joel S. Parker, Katherine A. Hoadley, Lisa A. Carey, Charles M. Perou, Jonathan S. Serody
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (14): 3818–3829.
https://doi.org/10.1158/1078-0432.CCR-13-3368
Published: 14 July 2014
View article titled, Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer
Open the PDF for Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice

Jerry Usary, Wei Zhao, David Darr, Patrick J. Roberts, Mei Liu, Lorraine Balletta, Olga Karginova, Jamie Jordan, Austin Combest, Arlene Bridges, Aleix Prat, Maggie C. U. Cheang, Jason I. Herschkowitz, Jeffrey M. Rosen, William Zamboni, Norman E. Sharpless, Charles M. Perou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (17): 4889–4899.
https://doi.org/10.1158/1078-0432.CCR-13-0522
Published: 02 September 2013
View article titled, Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Open the PDF for Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice in another window
Includes: Supplementary data
Journal Articles

Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes

David H. Nguyen, Erik Fredlund, Wei Zhao, Charles M. Perou, Allan Balmain, Jian-Hua Mao, Mary Helen Barcellos-Hoff
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1353–1362.
https://doi.org/10.1158/1078-0432.CCR-12-3554
Published: 14 March 2013
View article titled, Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes
Open the PDF for Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes in another window
Includes: Supplementary data